P2X7 receptor at the heart of disease

Hippokratia

Volumn 14, Issue 3, 2010, Pages 155-163

  Vasileiou, E ^a   Montero, R M ^b   Turner, C M ^b   Vergoulas, G ^c  

^a General Hospital of Kastoria   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

IL 1b ATP; NLRP3 infammasome; P2X7; Purinergic receptors; Purinergic signaling; Review

Indexed keywords

A 438079; ADENOSINE TRIPHOSPHATE; CATION CHANNEL; CYTOKINE; INTERLEUKIN 1BETA; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; CYTOKINE RELEASE; DEPRESSION; DRUG RECEPTOR BINDING; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; KNOCKOUT MOUSE; MACROPHAGE ACTIVATION; MOLECULAR CLONING; MULTIPLE SCLEROSIS; NEPHRITIS; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS;

EID: 77954627345     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Burnstock G.Purinergic nerves. Pharmacol Rev. 1972; 24: 509-581.
2. Burnstock G, Campbell G, Satchell D, Smythe A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol. 1970; 40: 668-688.
3. Ralevic V, Burnstock G. Receptors for purines and pyrimi-dines.Pharmacol Rev. 1998;50: 413-492.
4. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cy-tol.2004; 240: 31-304.
5. Burnstock G. Purinoceptors: ontogeny and phylogeny. Drug Dev Res. 1996a; 39: 204-242.
6. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, et al. Nomenclature and classifcation of purinoceptors.Pharmacol Rev. 1994;46:143-156.
7. Burnstock G. A basis for distinguishing two types of puri-nergic receptor. In: Straub RW, Bolis L (eds). Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Raven Press: New York.1978; 107-118.
8. Burnstock G, Pathophysiology and Therapeutic Potential of Purinergic Signaling, Pharmacological Reviews.2006;58:58-86.
9. Belgi R, Kobatake E, Aizawa M., Dubyak G.R.Detection of local ATP release from activated platelets using cell surface attached frefy luciferase. Am J Physiol Cell Physiol. 1999; 276: C267-C278.
10. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP triggers IL-1 release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 1997; 159: 1451-1458.
11. Fillipini A, Taffs RE, Agui T, Sitkovsky MV. EctoATPase activity in cytolytic T lymphocytes.Protection of the cytolytic effects of extracellular ATP.J Biol Chem. 1997; 265: 334-340.
12. Sabirov RZ, Okada Y. ATP-conducting maxi-anion channel: a new player in stress-sensory transduction. Jpn J Physiol. 2004; 54: 7-14.
13. Dubyak GR, el-Moatassim C. Signal transduction via P2-pu-rinergic receptors for extracellular ATP and other nucleotides. Am J Physiol Cell Physiol. 1993; 265: C577-C606.
14. Lazarowski ER, Boudher RC, Harden TK. Constitutive release of ATP and evidence for major contribution of ecto-nucleo-tide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem. 2000; 275: 31061-31068.
15. Nieber K, Eschke D, Brand A. Brain hypoxia: effects of ATP and adenosine. Prog.Brain Res. 1999; 120: 287-297.
16. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362: 299-309.
17. Schwiebert EM, Akos Zsembery, John P. Geibel.Cellular mechanisms and physiology of nucleotide and nucleoside release from cells: current knowledge, novel assays to detect purinergic agonists, and future directions. Curr Top Membr. 2003; 54: 31-58.
18. Egan TM, Cox JA, Voigt MM. Molecular structure of P2X receptors. Curr.Top.Med.Chem. 2004; 4: 821-829.
19. 7). Science. 1996; 272: 735-738.
20. 7. Cloning and expression of a human cDNA. J Biol Chem. 1997; 272: 5482-5486.
21. 7 receptor. FEBS Lett. 1998; 439: 26-30.
22. 7 receptor Neuro-pharmacology. 1997; 36: 1277-83.
23. 7 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle," Circulation Research. 1998; 83: 196-203.
24. 7 receptors: properties and relevance to CNS function. Glia. 2006; 15: 738-746.
25. Freist W, Verhey JF, Stuhmer W, Gauss DH. ATP binding site of P2X channel proteins: structural similarities with class II aminoacyl-tRNA synthetases. FEBS Lett. 1998; 434: 61-6514.
26. 7 receptor. J Biol Chem. 2004; 279: 31287-31295.
27. 7 receptor. Receptors Channels. 1998; 5: 347-354.
28. 7 contains multiple protein-and lipid-interaction motifs includ ing a potential binding site for bacterial lipopolysaccharide. J Immunol. 2001; 167: 1871-1876.
29. 7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immu nol. 2004; 172: 4987-4994.
30. North A. Molecular physiology of P2X receptors.Physiol Rev. 2002; 82; 1013-1067.
31. 7-transfected HEK293 cells. Mol Biol Cell. 2003; 14: 2655-2664.
32. Di Virgilio, F. The P2Z purinoceptor: an intriguing role in immunity, infammation and cell death. Immunol. 1995; 16: 524-528.
33. 7 Receptor Channel Activity J Biol Chem. 2008; 283: 25725-25734.
34. 7 ATP channel. Biochem Biophys Res Commun. 2005; 332: 17-27.
35. 7 receptor impairs ATP-induced IL-1 release from human monocytes. J. Immunol. 2004; 172: 3399-3405.
36. 7 purinergic receptor stimulation activate a common cytolytic pore. Am J Physiol. 1999; 277: C766-C776.
37. Verhoef PA, Kertesy SB, Estacion M, Schilling WP, Dubyak GR. Maitotoxin induces biphasic interleukin-1 secretion and membrane blebbing in murine macrophages. Mol Pharmacol. 2004; 66: 909-920.
38. Steinberg TH, Silverstein SC. Extracellular ATP4-promotes cation fuxes in the J774 mouse macrophage cell line.J Biol Chem.1987; 262: 3118-3122.
39. 7 receptor. J Biol Chem. 2001; 276: 11135-11142.
40. 7 receptor. J Biol Chem. 2003; 278: 17108-17113.
41. 7 function and impairs ATP-induced mycobacte-rial killing by macrophages. J Biol Chem. 2005; 281: 2079-2086.
42. 7 gene in 1-2% of the Caucasian population. FEBS Lett. 2005; 579: 2675-2678.
43. 7 gene with tuberculosis in a Gambian population. J Infect Dis. 2002; 186: 1458-1462.
44. 7 receptor activation amplifes lipopolysaccharide-induced vascular hyporeactivity via interleukin-1β release," J Pharmacol Exper Therap. 2008; 326: 864-870.
45. Wildman SS, King BF, Burnstock G. Modulation of ATP responses at recombinant rP2X4 receptors by extracellular pH and Zinc. B J Pharmacol. 1999; 126: 762-768.
46. + and Zn+ on ATP responses at rP2X1 and rP2X3 receptors. B J Pharmacol. 1999; 128: 486-492.
47. Xiong K, Peoples RW, Montgomery JP, Chiang Y, Stewart RR, Weight FF, et al. Differential modulation by copper and zinc of P2X2 and P2X4 function. J Neurophysiol. 1999; 81: 2088-2094.
48. Acua-Castillo C, Morales B, Huidobro-Toro JP. Zinc and copper modulate differentially P2X4 receptor. J Neurochem. 2000; 74: 1529-1537.
49. Clyne JD, LaPointe LD, Hume RI. The role of histidine residues in modulation of the rat P2X2 purinoreceptor by zinc and pH. J Physiol. 2002; 539: 347-359.
50. Lorca RA, Coddou C, Gazitiüa MC, Bull P, Arredondo C, Huidobro-Toro JP. Extracellular histidine residues identify common structural determinants in the copper/zinc P2X2 receptor modulation. J Neurochem. 2005; 95: 499-512.
51. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
52. Dinarello CA. Proinfammatory cytokines. Chest. 2000; 118: 503-508.
53. Dinarello CA. The IL-1 family and infammatory diseases. Clin Exp Rheumatol. 2002; 20: S1-S13.
54. Dinarello CA. Blocking IL-1 in systemic infammation. J Exp Med. 2005; 201: 1355-1359.
55. Dinarello CA. Unraveling the NALP-3/IL-1 infammasome: a big lesson from a small mutation. Immunity. 2004; 20: 243-244.
56. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood. 200; 97: 587-600.
57. Hogquist KA, Unanue ER, Chaplin DD. Release of IL-1 from mononuclear phagocytes. J Immunol. 1991; 147: 2181-2186.
58. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994; 269: 15195-15203.
59. Griffths RJ, Stam EJ, Downs JT, Otterness IG. ATP induces the release of IL-1 from LPS-primed cells in vivo. J Immunol. 1995; 154: 2821-2828.
60. Perregaux DG, Gabel CA. Human monocyte stimulus-coupled IL-1 beta posttranslational processing: modulation via monovalent cations. Am J Physiol. 1998; 275: 1538-1547.
61. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castag-noli P, Di Virgilio F. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol. 1996; 156: 1531-1539.
62. Ferrari D, Wesselborg S, Bauer MKA, Schulze-Osthoff K. Extracellular ATP Activates Transcription Factor NF-{kappa}B through the P2Z Purinoreceptor by Selectively Targeting NF-{kappa}B p65. J Cell Biol. 1997; 139: 1635-1643.
63. 7 receptors. J Biol Chem. 2001; 276: 125-132.
64. 7 receptor: a key play in IL-1 processing and release. J Immunol. 2006; 176: 3877-3883.
65. 7 nucleo-tide receptor in monocytes, macrophages, and HEK-293 cells. Am J Physiol Cell Physiol. 2003; 285: C286-C299.
66. 7 receptor. EMBO J. 2006; 25: 5071-5082.
67. Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin-and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem. 2007; 282: 2386-2394.
68. 7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol. 2008; 180: 7147-7157.
69. Martinon F, Burns K, Tschopp J. The infammasome: a molecular platform triggering activation of infammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10: 417-426.
70. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. Cryopyrin activates the infammasome in response to toxins and ATP. Nature. 2006; 440: 228-232.
71. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. Differential activation of the infammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004; 430: 213-218.
72. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, et al. Reconstituted NALP1 infammasome reveals two-step mechanism of caspase-1 activation. Mol Cell.2007; 25:713-724.
73. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity. 2001; 15: 825-835.
74. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Mat-teoli M, et al. Astrocyte-derived ATP induces vesicle shedding and IL-1 release from microglia.J.Immunol. 2005; 174: 7268-7277.
75. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubar-telli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for infammatory processes. Proc Natl Acad Sci. 2004; 101: 9745-9750.
76. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubar-telli A. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell. 1999; 10: 1463-1475.
77. Schwiebert EM. ATP release mechanisms, ATP receptors and purinergic signalling along the nephron. Clin Exp Pharmacol Physiol. 2001; 28: 340-350.
78. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell. 2005; 16: 3659-3665.
79. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmunity Reviews. 2005; 4: 162-170.
80. 7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (CREATE study). ACR/ARHP Annual Scientifc Meeting, presentation 2085 (Abstract)
81. 7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 2003; 278: 13309-13317.
82. Jun D, Kim K. ATP-mediated necrotic volume increase (NVI) in substantia nigra pars compacta dopaminergic neuron, Abstract Viewer/Itinerary Planner; Program 2004; 222. 18. Society for Neuroscience.
83. 7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007; 151: 571-579.
84. 7 receptors and implications for therapy. Int J Immunopathol Pharmacol. 2008; 2: 61-71.
85. 7 purinoceptor gene abolishes chronic infammatory and neuropathic pain. Pain. 2005; 114: 386-396.
86. Witting A, Chen L, Cudaback E, Straiker A, Walter L, Rickman B, et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proceed ings of the National Academy of Sciences of the United States of America. 2006; 103: 6362-6367.
87. 7 receptors in the nervous system. Progress in Neurobiology. 2006; 78: 327-346.
88. Fu W, McCormick T, Qi X, Luo L, Zhou L, Li X, et al. Activation of P2X(7)-mediated apoptosis Inhibits DMBA/TPA-in-duced formation of skin papillomas and cancer in mice. BMC Cancer. 2009; 9: 114.
89. 7-mediated chemoprevention of epithelial cancers. Expert Opin Ther Targets. 2009; 11: 1313-1332.
90. 7 Receptor: A Novel Biomarker of Uterine Epithelial Can cers. Cancer Epidemiol Biomarkers Prev. 2006; 10: 1906-1913.
91. 7-induced pore formation and apoptosis: an early effect of diabetes on the retinal microvascu-lature. Investig Ophthalmol Vis Sci. 2004; 45: 1026-1032.
92. Palomino-Doza J, Rahman TJ, Avery PJ, Mayosi BM, Farrall M, Watkins H, et al. Ambulatory Blood Pressure Is Associated With Polymorphic Variation in P2X Receptor Genes. Hypertension. 2008; 52: 980-985.
93. Gibbons GH. Autocrine-paracrine factors and vascular remodeling in hypertension. Current Opinion in Nephrology and Hypertension. 1993; 2: 291-298.
94. Ralevic V, Burnstock G. Involvement of purinergic signaling in cardiovascular diseases. Drug News and Perspectives. 2003; 3: 133-140.
95. Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules. J Am Soc Nephrol. 2006; 17: 1841-1847.
96. Vekaria RM, Shirley DG, Svigny J, Robert J. Unwin Immu-nolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol. 2006; 290: F550-F560.
97. Hillman KA Johnson TM, Winyard PJ, Burnstock G, Unwin RJ, Woolf AS. P2X(7) receptors are expressed during mouse nephrogenesis and in collecting duct cysts of the cpk/cpk mouse. Exp Nephrol. 2002; 10: 34-42.
98. Wilson PD, Hovater JS, Casey CC, FortenberryJA, Schwiebert EM. ATP release mechanisms in primary cultures of epithe-lia derived from the cysts of polycystic kidneys. J Am Soc Nephrol. 1999; 10: 218-229.
99. Belgi R, Kobatake E, Aizawa M, Dubyak GR. Detection of local ATP release from activated platelets using cell surface attached frefy luciferase. Am J Physiol Cell Physiol. 1999; 276: C267-C278.
100. 7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol. 2004; 63: 686-699.
101. Bodin P, Burnstock G. Purinergic signalling: ATP release. Neu-rochem Res. 2001; 26: 959-969.
102. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 1997; 185: 153-163.
103. 7 receptors into the plasma membrane of HEK293 cells. Toxicology. 2007; 238: 60-69.
104. Wirkner K, Kfalvi A, Fischer W, Günther A, Franke H, Grger-Arndt H, et al. Supersensitivity of P2X receptors in cerebrocortical cell cultures after in vitro ischemia. J Neuro-chem.2005; 95: 1421-1437.
105. 7 nucleotide receptor expression by pro- and anti-infammatory stimuli in THP-1 monocytes. J Leukoc Biol. 1998; 64: 265-273.
106. 7 receptor expression and function in human astrocytes. Glia. 2005; 49: 245-258.
107. 7 ATP receptor modulates renal cyst development in vitro. Biochemical and Biophysical Research Communications. 2004; 332: 434-439.
108. Turner CM, Ramesh B, Srai SK, Burnstock G, Unwin RJ. Altered ATP-sensitive P2 receptor subtype expression in the Han: SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease. Cells Tissues Organs. 2004; 178: 168-179.
109. 7 purinocep-tor-stimulated TGF-βeta 1 mRNA expression involves PKC/ MAPK signalling pathway in a rat brain-derived type-2 astro-cyte cell line, RBA-2. Cell Signal. 2003; 15: 1129-1137.
110. Solini A, Ricci C, Chiozzi P, Amadio L, Pricci F, Di Mario U, et al. Purinergic modulation of mesangial extracellular matrix production: role in diabetic and other glomerular diseases. Kidney Int. 2005; 67: 875-885.
111. 7 receptors in the infammation and fbrosis of unilateral ureteral obstruction in mice. Kidney Int. 2006; 70; 1599-1606.
112. Klahr S. Urinary tract obstruction. Semin Nephrol. 2001; 21: 133-145.
113. Klahr S, Morrissey J. Obstructive nephropathy and renal fbrosis. Am J Physiol Renal Physiol. 2002; 283: F861-F875.
114. Diamond JR. Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis. 1995; 26: 133-140.
115. Diamond JR, van Goor H, Ding G, Engelmyer E. Myofbro-blasts in experimental hydronephrosis. Am J Pathol. 1995; 146: 121-129.
116. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gob G, Johnson DW. Interleukin-1 induces human proximal tubule cell injury, -smooth muscle actin expression and fbronectin production. Kidney Int. 2002; 62: 31-40.
117. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gob G, Johnson DW. Interleukin-1beta stimulates human renal fbroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism. J Lab Clin Med. 2002; 140: 342-350.
118. Harada H, Chan CM, Loesch A, Unwin R, Burnstock G. Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int. 2000; 57: 949-958.
119. 7 receptors. Am J Physi-ol. 1998; 275: F962-F969.
120. Turner CM, Vonend O, Chan C, Burnstock G, Unwin RJ. The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistological study. C Cell Tissues Organs. 2003; 175:105-117.
121. Vovend O, Turner CM, Chan CM, Loesch A, Dell'Anna GC, Srai KS, et al. Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int. 2004; 66: 157-166.
122. 7 receptor-mediated function in human primary fbroblasts. Diabetologia. 2000; 43: 1248-1256.
123. 7 Activity in Human Fibroblasts From Diabetic Patients.Arteriosclerosis. Thrombosis and Vascular Biology. 2004; 24: 1240.
124. 7 receptor in experimental and human glomeru-lonephritis. Nephrol Dial Transplant. 2007; 22: 386-395.
125. 7 Defciency Attenuates Renal Injury in Experimental Glomerulonephritis. J Am Soc Nephrol. 2009; 20: 1275-1281.